Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trial assessing the importance of nephrectomy in metastatic renal cell carcinoma
ISRCTN19562321Phase 3Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- May 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sunitinib in clear cell renal cell carcinoma (ccRCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Overall survival. Started May 2011; status: completed.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on ISRCTN19562321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19562321.